The life sciences industry faces an increasingly competitive landscape, yet the opportunities available in the market continue to grow. The UK government is committed to expanding the life sciences industry to strengthen the R&D and manufacturing industries within the UK. Changes in medicine, digital, and data are creating more opportunities than ever before to improve patient outcomes, meaning that partnering with the NHS can become more complex for life sciences organisations. We give our clients an edge and help them to take bold steps forwards to better engage with healthcare systems.
What a consultancy can do to support you:
We support clients with just some of these areas
- Identify partnerships for you, which are relevant to your business needs
- Help you build meaningful relationships with NHS stakeholders
- Understand how to navigate NHS and government regulations
- How to present ideas and recommendations aligned to NHS ways of working
- Discover the opportunities of population health data
- Make use of data to support the discovery, development and uptake of new medicines
- Identify where the biggest opportunities are to improve performance in your products
- Help you improve outcomes across the whole pathway
- Demonstrate the value of a multi-channel environment
- Maximise the uptake of new therapies
Why use CF on your journey to discovery:
With our deep insights into the NHS, CF is uniquely placed to facilitate effective knowledge-sharing and partnerships.
- Worked with over 20 systems across the UK over the past 10 years
- Delivered recommendations which have then become the standard by NHS systems
- Experience of connecting payors and providers and demonstrating the value to the payor on their own terms
- Production of outcome payment models based on in-depth analytics
- Analytics department creates an in-depth analysis of population health to determine the value of opportunity for both parties
- Extensive analytical tools and models to understand the impact of all potential scenarios
- Blended CF team from life sciences, consultancy, clinical practice and senior NHS roles
CF worked with a global pharmaceutical company to drive a new approach to collaborative action between our client and the NHS to improve outcomes across the patient pathway: from prevention through to early detection, intervention and best practice treatment.
• Assessed potential geographical and therapeutic areas in which to pursue the partnership
• Synthesised analysis, research and expert interview feedback to understand the main causes of poor outcomes and prioritise levers for improvement (e.g. early diagnosis)
• Developed an economic model to quantify the potential impact of the levers
• Gained agreement from all partners to take the proposal forward to the next stage of specificity
Building a new partnership model with the NHS to maximise patient outcomes
Our client was a global pharmaceutical company who develop medicines across many therapeutic areas. The company sought to test a new model of partnership with the NHS to maximise patient outcomes. They had a clear desire to ‘do something different’ but were not able to realise the desire into a clear idea of how to transform that into a reality.
They were interested in supporting the NHS more broadly across a patient pathway, from prevention through to early detection and intervention, including pathway optimisation (to shorten waits for treatment and improve access to effective new treatments). The new model of the partnership had to align the incentives of all parties, combine existing capacities and – ultimately – create a sustainable NHS-industry relationship.
As a first step, the company wanted to work with specific local health systems to explore what a new partnership approach could look like with the NHS.
Choosing the right partner to deliver an impactful approach
CF was commissioned to lead engagement to design the potential model of partnership, evaluate its potential impact, and support the initial engagement with the NHS stakeholders. CF was chosen due to the unique position we hold:
• We have deep knowledge of how both the NHS and the pharmaceutical industry works
• Ability to work as a neutral third party to facilitate building stronger relationships between pharmaceutical companies and our extensive network in the NHS
• The CF analytics team have a strong understanding of healthcare data and information governance, and access to national datasets
Development of the proposal for a partnership model
To understand the opportunity to improve outcomes, we conducted interviews and synthesised feedback from a wide range of stakeholders, including national stakeholders (NHS England and Improvement) and potential local partners.
We examined quantitative data in the therapeutic space to understand the current performance level of the NHS across all geographic areas to identify areas of greatest need and variation in performance.
With the input from this qualitative and quantitative work, we were able to narrow in on the target areas for improvement across the pathway and to shortlist a small number of areas to consider as partners for this work.
We developed an economic model which was used to support discussions with the NHS, which quantified the impact of the levers of patient outcomes, treatment volumes and cost to the NHS.
We then led the engagement to develop a proposal for a new partnership model, which included overall goals, which required input from all parties, information governance requirements, and concrete next steps to take the concept forward.
We captured our work in a compelling report which was continuously refined over several months based on expert feedback.
Engagement to secure commitment to the implementation
We delivered a role-play workshop for our client that simulated the initial engagement with the NHS. This allowed our client to build a strong message that resonated with the needs and expectations of potential partners.
We then facilitated initial engagement with potential partners, which resulted in agreement from all involved to take the proposal to the next stage.
This project has built a foundation for a partnership between the NHS and pharmaceutical industry which has the potential to profoundly improve patient outcomes in a financially sustainable way.